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Abstract
Objective—To examine patterns of early brain growth in young children with fragile X
syndrome (FXS) compared to a comparison group (controls) and a group with idiopathic autism.
Method—The study included 53 boys between 18–42 months of age with FXS, 68 boys with
idiopathic autism (ASD), and a comparison group of 50 typically-developing and
developmentally-delayed controls. We examined structural brain volumes using magnetic
resonance imaging (MRI) across two timepoints between ages 2–3 and 4–5 years and examined
total brain volumes and regional (lobar) tissue volumes. Additionally, we studied a selected group
of subcortical structures implicated in the behavioral features of FXS (e.g., basal ganglia,
hippocampus, amygdala).
Results—Children with FXS had greater global brain volumes compared to controls, but were
not different than children with idiopathic autism, and the rate of brain growth between ages 2 and
5 paralleled that seen in controls. In contrast to the children with idiopathic autism who had
generalized cortical lobe enlargement, the children with FXS showed a specific enlargement in
temporal lobe white matter, cerebellar gray matter, and caudate nucleus, but significantly smaller
amygdala.
Conclusions—This structural longitudinal MRI study of preschoolers with FXS observed
generalized brain overgrowth in FXS compared to controls, evident at age 2 and maintained across
ages 4–5. We also find different patterns of brain growth that distinguishes boys with FXS from
children with idiopathic autism.
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Fragile X syndrome (FXS) is a well characterized X-linked genetic disorder and the leading
heritable cause of intellectual disability.1 Boys with the FXS full mutation have been
reported to show social deficits with peers, abnormalities in communication, unusual
responses to sensory stimuli, stereotypic behavior, social avoidance, and gaze aversion.2–7
Approximately one third of individuals with FXS meet criteria for autistic disorder,3,8 while
1–3% of individuals with autistic disorder are identified to have FXS. Autism is a clinically
heterogeneous disorder without a known specific genetic mechanism. Conversely, FXS is a
single gene disorder and provides a more circumscribed way to examine the impact of
aberrant brain mechanisms and development.
Giedd et al.9 have demonstrated the utility of longitudinal brain development studies in
typical development and documented nonlinear brain growth. This approach is particularly
relevant when examining brain changes in a neurodevelopmental disorder that many involve
nonlinear changes over time. There is a critical need for longitudinal brain imaging studies
in conditions such as fragile X, where behavioral changes across development have been
reported (e.g., increase in repetitive behaviors at school-age). Better characterization of the
changing patterns in brain growth over time may provide clues to underlying mechanisms
and can better depict the phenotype of FXS across development.
This report is from a longitudinal magnetic resonance imaging (MRI) study of brain
development in preschoolers with FXS. In a cross-sectional volumetric MRI study of this
sample,10 toddlers with FXS (18–42 months old) were found to have enlarged caudate
nucleus (CN) and smaller amygdala (AMY) volume compared to controls, while the
toddlers with idiopathic autism (iAUT) had a different profile, showing only modest CN
enlargement and significantly larger AMY. Voxel based morphometry (VBM) studies of
this sample examined FXS compared to controls and found larger gray matter volume
(GMV) in CN, thalamus, and fusiform gyrus and decreased GMV in cerebellar vermis
present at both timepoints in the FXS group.11,12 White matter volume (WMV) was
observed to be larger in frontal striatal regions in the boys with FXS compared to controls
and became more pronounced over time.12 A cross-sectional comparison study using
VBM13 examined the FXS group compared to iAUT and observed different patterns of
brain volumes in the iAUT and control group compared to FXS. Notably, using this
different methodology the pattern of greater CN and reduced AMY that was seen in the
volumetric ROI analysis10 was seen in the FXS group versus iAUT. These VBM studies
provide converging data for our structural MRI findings pointing to a specific pattern of
larger CN and implicate cerebellar, thalamic, and temporal lobe pathways associated with
FXS.
In this paper, we extend our previous work (10) by comparing the longitudinal brain volume
data from this sample of boys with FXS to a sample of boys with iAUT. We addressed three
questions about our group FXS: (1) Were there differences in brain volumes compared to
age and IQ matched male controls? (2) Were there differences in brain volumes compared to
males with iAUT? and (3) What was the pattern of brain volumes in those boys with FXS
who were comorbid for autism? For each of these questions, we examined global brain
volumes (e.g., GMV, WMV), regional brain volumes (e.g., cortical lobes), and a set of
selected substructures of interest (e.g., CN, AMY).
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The study included 53 male children with fragile X syndrome (FXS), 68 children with
idiopathic autism (iAUT), and 50 comparison cases who were enrolled in this longitudinal
study between 18–42 months of age and received an initial behavioral assessment and brain
MRI scan. Approximately two years later, at age 4-5 years old, this cohort of children
received a repeat assessment and MRI. At follow-up, the sample contained 39 boys with
FXS, 44 boys with iAUT, and 26 comparison cases. The comparison group was comprised
of typically developing children (TYP) and children with developmental delay (DD) who
had no evidence of a pervasive developmental disorder (PDD). The group with ASD was
observed to be lower functioning (estimated IQ in the 50s) while the TYP fell in the average
range (estimated IQ ~100). The DD control group was included to enrich the comparison
sample for low IQ non-autistic subjects since our sample of FXS and iAUT was comprised
of children with lower intellectual functioning.
See Table 1 for a description of subject characteristics. At time 1 there were a total of 50
children in the comparison group (31 TYP, 19 DD); at time 2 there were 26 cases (19 TYP,
7 DD). For exploratory analyses, a subgroup of the FXS sample was identified who met
criteria for autism on the Autism Diagnostic Interview–Revised (ADI-R) and ADOS (FXS
+Aut) (time 1 = 16, time 2 = 13), and the remaining subjects were identified as not meeting
criteria (FXS-Aut) (time 1 = 37, time 2 = 26). All subjects in the study were male.
A full description of the ascertainment and inclusion criteria is reported elsewhere,10 but a
brief summary is included here. All subjects were enrolled between 18–42 months of age
(time point 1) and seen for a repeat assessment approximately 24 months after their initial
assessment (time point 2). At study enrollment, medical records and developmental history
were reviewed and records were re-evaluated at time point 2. Inclusion in the FXS group
required DNA testing confirming the fragile X full mutation. Children with iAUT were
referred after receiving a clinical diagnosis of autistic disorder which was confirmed with
clinical testing (see below). Subjects with DD were referred only if they had no known
identifiable cause for their delay (e.g., prematurity, genetic or neurological disorder) and had
no indication of a pervasive developmental delay. The TYP subjects were recruited from the
community and were screened for an autism spectrum disorder (ASD). All subjects with
iAUT, DD, and TYP were excluded for evidence of fragile X syndrome, Tuberous Sclerosis
(TS), gross CNS injury (e.g., cerebral palsy, significant pregnancy complications or
perinatal/postnatal trauma, drug exposure), prematurity (<34 weeks), low birth weight
(<2000 g), seizures, and significant motor or sensory impairments. Additionally, the DD and
TYP children were screened for autism with the Childhood Autism Rating Scale14 and
excluded if they met the cutoff for autism (> 25 total score). All autistic and DD subjects
received DNA testing to exclude FXS.
Study approval was acquired from the University of North Carolina (UNC) and Stanford
Institutional Review Boards and written informed consent was obtained by getting parental
(or custodial guardian) consent for each subject.
Clinical Assessment
Medical records and developmental history were reviewed for all subjects at the time of
entry to the study. Inclusion in the FXS group required DNA testing confirming the fragile
X full mutation as diagnosed with standard Southern Blot technique. These children also
received testing for the fragile X mental retardation protein (FMRP) expression by
calculating the percentage of peripheral lymphocytes containing FMRP using
immunostaining techniques.15 Some subjects with autism were included from another study
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and criteria for that study have been described elsewhere.16 Briefly, children were referred
to that study after receiving a clinical diagnosis of autism, which was then confirmed by our
team using the ADI-R17 and the Autism Diagnostic Observation Schedule-G (ADOS-G)18
scores. Subjects were only included in the iAUT group if they met criteria for autism in all
domains of the ADI-R and obtained ADOS-G consistent with autism. The same assessments
were used at time point 2 (age 4–5 years) and a small subset of subjects failed to meet the
original study criteria for autistic disorder (e.g., ADI-R, ADOS-G, DSM-IV) but continued
to show evidence of symptoms consistent with a PDD-NOS diagnosis. These subjects were
classified as PDD. The iAUT sample therefore included 61 autism and 7 PDD subjects at
time 1, and 39 autism and 5 PDD subjects at time 2. Inclusion in the DD group was defined
as having significant global delays (developmental IQ < 80), scores consistent with DD on
the other assessment measures, no known identifiable cause for their delay (on medical
record review), and no indication of PDD. Inclusion in the TYP group was defined as having
average developmental and cognitive abilities (i.e. developmental IQ > 85).
All subjects were given a battery of measures including the Mullen Scales of Early
Learning,19 Differential Abilities Scale (DAS)20 (at time 2 only), the Vineland Adaptive
Behavior Scales,21 behavioral rating scales (e.g., Aberrant Behavior Checklist,22 Repetitive
Behavior Scales23), and a standardized neurodevelopmental examination to exclude subjects
with any notable dysmorphology, evidence of neurocutaneous abnormalities, or other
significant neurological abnormalities.
Table 2 presents the cognitive and adaptive functioning characteristics of the sample. Many
of the subjects with FXS, iAUT, and DD failed to obtain a valid standard score on the DAS
at time point 2, so we only provide estimates of cognitive functioning from their Mullen.
MRI Acquisition
All subjects were scanned on a 1.5 Tesla GE Signa MRI scanner (GE Imagine Systems,
Milwaukee, WI) at either the Lucile Packard Children’s Hospital (Stanford) or the Duke–
UNC Brain Imaging and Analysis Center (BIAC). Image acquisition was designed to
maximize gray/white tissue contrast for the pediatric brain and included: (1) a coronal T1 IR
Prepared: T1 300 msec, TR 12 msec, TE 5 msec, 20° flip angle, at 1.5 mm thickness with 1
NEX, 20 cm FOV; and 256 x 192 matrix; (2) a coronal PD/T2 2D dual FSE, TR 7200 msec,
TE 17/75 msec, at 3.0 mm thickness with 1 NEX, 20 cm FOV, and 256 x 160 matrix. A
series of localizer scans and a set of phantoms was used to standardize assessments across
sites and time (for the longitudinal study). The in-plane voxel resolution for the T1 and
PDT2 scans are as follows: T1 scans: 0.78125 x 0.78125 x 1.50; PD/T2 scans: 0.78125 x
0.78125 x 3.0. Both scans are then resampled to isotropic (1.01562 x 1.01562 x 1.01562)
with our BRAINS2 software during the registration process.
Subjects with FXS, autism and DD were scanned using sedation administered by a sedation
nurse and/or under the supervision of a pediatric anesthesiologist. Physiological monitoring
was conducted throughout the scan and recovery. TYP subjects were scanned without
sedation, in the evening, while sleeping. At age two all the TYP subjects were scanned in the
evening, while sleeping. At age 4, some of the TYP subjects (n=5) were scanned while
awake, after completing a behavioral training protocol to learn to lie still in the scanner. The
remaining TYP subjects were scanned while sleeping for time point 2. All MRI scans were
reviewed by a pediatric neuroradiologist and screened for significant abnormalities (e.g.,
malformations, lesions, etc.).
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The image processing procedures for this data are identical to those described in the initial
volumetric paper from this longitudinal study.10 The primary components are briefly
reported here for reference. Scans first underwent quality control checks to determine if they
were of sufficient quality to process. The T1 and PD/T2 scans were then registered and
aligned into a standardized plane along an AC-PC (anterior-posterior commissure) axis.24
The co-registered and aligned images were then processed for tissue segmentation using the
Expectation Maximization Segmentation (EMS) pipeline.25 An “averaged” pediatric
probabilistic brain atlas was aligned to each subject brain using a linear, affine
transformation in a fully automated procedure. The automated procedure included bias
estimation, inhomogeneity correction, and non-brain stripping procedures. Gray, white, and
CSF tissue segmentations were produced for each subject. Total brain volume (TBV)
measures included total gray and white matter and all CSF. Total tissue volume (TTV)
included all gray and white matter in the cerebrum (cerebral cortical volume), cerebellum,
and brainstem.
Regional lobe measurements were obtained using a manually parcellated template (atlas)
MRI of pediatric brain developed by our group (16), which was then mapped onto each
subject brain using a fluid high-dimensional deformation algorithm (described in Hazlett et
al., 2005).16 Delineated regions included the frontal, temporal, parietal, and occipital lobes,
cerebellum, corpus callosum, and a “subcortical area” (basal ganglia, thalamus, deep white
matter, and brainstem). The insula and cingulate gyrus were also defined, but for the
purposes of these analyses the insula was included in the cerebral cortex measure and
cingulate with the frontal/parietal lobes. Cortical label maps were combined with the EMS
tissue classified images to produce gray/white/CSF volumes for each of these lobe
compartments.
Selected subcortical structures were measured using region-of-interest protocols which are
described elsewhere.10 Right and left volumes for the caudate nucleus (CN), putamen
(PUT), globus pallidus (GP), amygdala (AMY), and hippocampus (HIPP) were obtained
using semi-automated or manual protocols.
Data Analysis
Descriptive statistics and data plots were first examined to look for outliers. No anomalous
data was observed or removed. A priori hypotheses were tested using general linear mixed
models with repeated measures in SAS 9.1. In all models brain volume was the dependent
variable and diagnostic group (FXS, iAUT, DD, TYP), age, and IQ were independent
variables. Time was entered as a repeated measure. Group differences in developmental
patterns were examined by testing the age X group interactions. For each group of analyses
(total brain, cortical lobes, substructures) two models were fit to the data: (1) the first model
included group, age and IQ, (2) the second model added TBV as a covariate to evaluate
whether any of the differences in brain volumes were disproportionate to differences
observed for TBV (in the lobes or subcortical regions). All analyses adjusted for the effects
of age and IQ ratio on the measured brain volume by including them as covariates. Data
collection site (UNC, SU) was not included as a predictor because no systematic difference
in brain volumes (GM, WM, CSF, TTV, and 5 substructures of interest) were observed
between sites.12 Laterality was assessed by examining the significance of interactions
between group and hemisphere (left or right ‘side’).
Age and IQ were scaled to aid interpretation of the results. Age was centered at 3.5 years
which was close to the overall mean of 3.6 years. An IQ ratio was calculated by dividing the
child’s age equivalent score on the Mullen Visual Reception subscale by the child’s actual
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age. This allows a more precise measure of children’s nonverbal abilities who would
otherwise score at the lower end of the standardized scale and be assigned values below a
basal standard score (‘<49’). This IQ ratio was then centered which was the mean for all
observations. The rescaling of these variables results in all main effects being estimated at
these values unless otherwise specified.
Analyses were organized to examine the following group comparisons: (1) FXS compared
to controls, (2) FXS compared to iAUT, and (3) FXS subgroups (with or without autism)
compared to iAUT. Our first model focused on three group comparisons (FXS vs. iAUT vs.
Controls). For these comparisons, combined estimates for ‘controls’ (DD + TYP) was
created using post-estimation commands to create weighted averages. By using a weighted
average of the subgroups the combined group estimates are accurate estimates of the means,
while the possible error variance that could be accounted for by mean group differences is
minimized. Our secondary analysis included the subgroup comparisons (FXS+Aut, iAUT,
DD, TYP). However, only a single model was fit to obtain these estimates.
Tables 1 and 2 describe the sample characteristics. Age differences were observed (the TYP
subgroup was slightly younger than the other groups) and, therefore, age was included as a
covariate. Developmentally-delayed subjects were included in the control group to control
for IQ differences. While IQ was not found to be a significant predictor between groups,
comparisons were run with IQ as a covariate to be conservative. Study retention rates were
as follows: FXS+Aut (81%), FXS-A (70%), TYP (61%), iAUT (63%), and DD (37%). We
saw no differences in our results when we removed subjects who did not complete both time
points for the study, so the results below include those cases. We also examined descriptive
statistics for the FXS and then comparison group and did not find any significant difference
in age, developmental IQ, adaptive functioning, or on symptom severity as reported on the
ADI-R (for the FXS and iAUT groups only) between subjects who completed the study (2
time points) versus those who dropped out (1 time point).
Differences between the groups controlling for age and IQ were examined. While all the
groups showed an increase over time in brain volume for all areas measured, there were no
significant group differences in the rate of brain growth over time. Because age by group
interactions were not significant, only the main effect of group (averaged over time) is
reported. Interactions with side (right/left) were not significant, therefore results are reported
as total volume (sides combined).
Results
(1) FXS compared to controls
Raw means for FXS and control groups for total brain (TBV), total gray matter (TGM) and
total white matter (TWM) volumes are displayed in Table 3.
As age by group interactions were not significant, only main effect of group (averaged over
the 2 to 4–5 year age interval) is reported. Mean group differences are reported in Table 4.
Subjects with FXS had significant enlargement in TBV, total tissue volume (TGM+TWM,
or TTV), TGM, and TWM compared to controls after adjusting for age and IQ. The regional
comparisons (cerebrum, cerebellum, cortical lobes) were adjusted for age, IQ and TBV.
Temporal lobe white matter volumes remained significantly increased in the FXS group
compared to controls, while small but significant reductions in cerebral gray matter,
cerebellar white matter, and frontal gray matter were observed. Exploratory examination of
the control subgroups (DD, TYP) revealed that total brain enlargement in FXS compared to
controls was largely driven by smaller brain volumes in the DD group with the exception of
temporal lobe white matter volume, which was significantly enlarged in the FXS group
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compared to both the DD (p<.001, 10% difference) and TYP (p<.001, 10% difference)
controls after adjusting for age, IQ, and TBV.
Using data adjusted for age only, the FXS group had significant enlargement in caudate
(40%), globus pallidus (18%), and putamen (8%). This was true for total (combined) volume
as well as for right/left side. After controlling for age, IQ, and TBV, the findings remained
significant although the percent of enlargement observed was slightly less: caudate (34%),
globus pallidus (15%); and putamen (5%). The robust enlargement in the caudate and globus
pallidus remained significant compared to both DD and TYP subgroups (using either
volumes adjusted only for age, or for age/IQ/TBV). The enlargement in the putamen was
significant for both subgroups (DD and TYP) when examining age only corrected data, but
only for the TYP subgroup when using all covariates (age/IQ/TBV). The total, left, and right
amygdala volumes were smaller in the FXS group compared to controls (−9%). Amygdala
volumes (total, left, and right) were smaller compared to all subgroups (by about 4–6%), but
differences were significant with the DD subgroup only when adjusting for age/IQ/TBV (by
11%). Left hippocampus was also significantly smaller in FXS compared to controls (−7%)
and the TYP subgroup (−7%) when controlling for age/IQ/TBV. Comparisons for the
substructure volumes, controlling for age/IQ/TBV, are displayed in Table 5.
There was no difference between the FXS and controls in their rate of brain growth during
the age interval studied (2–5 years) for TBV, total tissue volume (TGM+TWM, or TTV),
TGM, TWM, and total CSF. These results indicate that differences in overall volume, first
observed at age 2, are maintained throughout the age interval i.e., the rate of change over the
interval is no different between cases and controls. The trajectories of brain growth for TBV
are displayed in Figure 1. The pattern for substructures (CN, AMYG, etc.) did not reveal any
group differences.
(2) FXS compared to iAUT
There were no significant brain volume differences in global volumes (TBV, TTV, TGM,
TWM) between individuals with FXS and iAUT. We have previously demonstrated
increased volume of these structures in individuals with iAUT versus controls (with typical
development and developmental-delay, who did not have either autism or FXS) (16). After
controlling for age, IQ, and TBV, the FXS group had significantly enlarged total cerebellum
(diff 5.09 (1.7), p = .003) and cerebellar gray matter (diff 4.97 (1.5), p=.001). Total cerebral
cortical volume was significantly less in FXS compared to iAUT (diff −11.02 (3.3), p<.001),
due to smaller cortical gray matter volume in FXS (diff −11.45 (2.8), p<.001). The FXS
group had significantly greater temporal lobe WM volume (diff 3.25 (0.7), p<.001) but all
frontal lobe volumes were significantly smaller in FXS compared to the iAUT group (frontal
lobe diff −10.82 (3.1), p<.001; frontal GM diff −7.67 (2.3), p<.001; frontal WM diff −3.15
(1.3), p=.013) (Figure 2). There were no significant differences observed in any of the
parietal- occipital volumes measured (total, GM, WM). The FXS group had significantly
greater caudate volume (29%), globus pallidus (7%), and putamen (6%) versus iAUT, and
findings did not differ with age-only adjusted volumes or the age/IQ/TBV adjusted. Both
amygdala and hippocampus were significantly smaller in the FXS group compared to the
iAUT group, using either age only or age/IQ/TBV adjustments.
There was no difference between the FXS and iAUT in their rate of brain growth during the
age interval studied (2–5 years) for any of the brain volumes we examined.
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(3) FXS subgroups (with or without autism) compared to iAUT Table 6 provides scores for
individuals with FXS who met criteria for autism
(FXS+Aut) and those with FXS who did not meet criteria for autism (FXS-Aut) on the
autism behavioral assessment measures (i.e., ADI-R and ADOS). Comparisons between
FXS+Aut subgroup and the iAUT group revealed no differences in total brain volumes
(TBV, TGM, TWM), but significantly larger total cerebellum (p=.03, 4%) and cerebellar
GM (p=.01, 5%), and significantly smaller total cerebral cortex (p=.006, -1%) and cerebral
cortical GM (p<.001, −2%) observed in the FXS+Aut subgroup versus iAUT. The FXS+Aut
subgroup also had significantly larger temporal lobe WM (p=.001, 8%) and smaller frontal
lobe volumes (total p=.004, −3%; WM p=.04, −3%; GM p=.007, - 3%) compared to the
iAUT group.
The FXS-Aut subgroup had significantly larger total cerebellum (p=.001, 5%) and cerebellar
GM (p<.001, 5%) volumes, and significantly less total cerebral cortex (p=.002, −1%) and
cerebral cortex GM (p=.003, −1%) versus iAUT and significantly larger temporal lobe WM
(p<.001, 8%) and reduced frontal lobe volumes (total p<.001, −3%; WM p=.02, −2%; GM
p<.001, −3%) versus the iAUT group.
There were no differences between the FXS subgroups (FXS+Aut vs. FXS-Aut) for any of
the subcortical volumes, although the trajectory between 2 and 4-5 years of age did appear
to be different, but not significantly (see Figure 3). The pattern of enlarged caudate, globus
pallidus, and putamen, and smaller amygdala and hippocampus volumes was the same for
the FXS with and without autism subgroups compared to iAUT (see Table 7).
Discussion
Children with FXS were observed to have increased total brain, total tissue, total gray
matter, total white matter, and temporal lobe white matter in comparison to controls.
Cerebral cortex gray matter, cerebellar white matter, and frontal lobe gray matter volumes
were noted to be slightly decreased in the FXS group compared to controls. We did not
observe any group differences in the rate of brain growth between groups, meaning that the
rate of brain growth across the interval from 2 to 5 years of age in children with FXS
paralleled that seen in controls. This would suggest that, for the brain regions assessed with
the methods described here, brain overgrowth had its onset prior to the first measurement at
2 years of age.
In comparison to a control group composed of both TYP and DD, and a contrast group
consisting of children with iAUT, the children with FXS showed a unique pattern of brain
volume measurements. Whereas, for the most part, children with FXS showed generalized
enlargement of both gray and white matter volume in the cerebral cortical lobes in contrast
to controls, enlargement was less robust than that observed in children with iAUT, with the
exception of a more striking, disproportionate enlargement of temporal lobe white matter in
children with FXS (as compared to both controls and those with iAUT). Temporal lobe
white matter volume was the only cortical volume in individuals with FXS to show
significant enlargement after adjustment for TBV, suggesting a specific neuroanatomical
signature that goes beyond the generalized cerebral cortical volume enlargement seen in
both FXS and iAUT. Temporal lobe white matter was also a region observed to be enlarged
in the VBM study by Hoeft et al., (2011) (13). Specific differences were also observed in the
cerebellum where FXS subjects showed significant enlargement of cerebellar gray matter
volume in contrast to individuals with iAUT.
The pattern of subcortical volume changes also showed a specific pattern over time,
consistent with previous reports by our group looking at brain volumes at age two years10
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and voxel-based morphometric measurements throughout this early age interval.11,12
Specifically, here we report a stable increase in volume, maintained over this two year age
interval, in basal ganglia structures, with a striking, persistent increase in caudate volume
(34%), followed by globus pallidus (15%) and putamen (5%); along with a decreased
volume of the amygdala, predominantly noted on the right side. In contrast to children with
iAUT, where we have previously reported enlargement of the amygdala with a more modest
but significant enlargement of caudate volume, children with FXS show a pattern of
markedly increased caudate volume with significantly decreased volume of the amygdala
that is present at 2 and maintained across early development. The robust caudate
enlargement (by over 30%) replicates our earlier reports on this sample at age 2–310,13 and
is consistent with observations in older individuals with FXS.26,27
Our findings of a specific pattern unique to FXS (in contrast to iAUT) are consistent with
behavioral reports of distinct social and communicative profiles for children with FXS and
ASD.28 Work examining 9–12 month old infants with FXS finds evidence for a specific
pattern of motor-sensory deficits that can be distinguished from infants with DD and ASD
(by diagnosis at later age).29 Specifically, problems with motor planning, repetitive
movements and repetitive use of objects were observed, making these motor-sensory deficits
some of the earliest detectable features of FXS. Our observation of significant basal ganglia
enlargement is consistent with these behavioral findings and suggests these brain differences
may be present from a very early age, if not prenatally.
Of note, reports about the molecular biology of FXS suggest a possible mechanism for brain
growth patterns observed in this study. Harlow et al.30 has demonstrated that FMRP inhibits
the generation of progenitor neurons from radial glia in mouse cerebral cortex, suggesting
that lack of FMRP, as seen in FXS, might result in an increased proliferation of progenitor
cells and subsequent cerebral cortical overgrowth. Alternatively, FMRP has been shown to
act as a regulator of dendritic mRNA.31 There are a number of hypotheses about the role of
FMRP in brain growth that could help explain specific pattern of brain development we find
in FXS. Work with the Fmr1 knock-out mouse has identified FMRP as playing a specific
role in neocortical development.32 FMRP has been shown to act as a regulator for dendritic
mRNA33 and the lack of FMRP has been linked to defects in the differentiation and
migration of neural progenitor cells in the neocortex.33 BDNF and trkB signaling in the
neural progenitor cells plays a critical role in normal cortical development, and these
signaling pathways function aberrantly in the neuroplast of the FXS knockout mouse.34
Grossman and colleagues35 proposed that FMRP acts as a general regulatory process over
dendritic spine loss, maturation, and formation, and that this could explain why different
brain regions may display different ‘phenotypes’. Our findings for specific patterns of
enlargement (e.g., basal ganglia, cerebellum) as well as diminished size (amygdala) in
young children with FXS would support this hypothesis.
These findings have significance for expanding our understanding about the
neurodevelopmental mechanisms underlying FXS. The presence of early brain differences
(evident by age 2) in young children with FXS points to aberrant early brain development in
this condition. Examining brain growth in infants with FXS, and perhaps including both full
and premutation cases may further illuminate the pathogenesis and provide additional clues
for mechanisms to target for intervention during vulnerable periods of brain growth. This
study also highlights the importance of longitudinal studies to help define the trajectory of
brain development. Studying the trajectory of brain development as children enter school
age would provide clues to better understand the effectiveness of targeted pharmacological
interventions (e.g., mGluR5) on brain growth. Lastly, these data continue to point to a
specific neuroanatomical signature for FXS that differs from that seen in iAUT, suggesting
the importance of studying the neurobiological basis of autistic behavior in more
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etiologically-defined and etiologically-homogeneous disorders such as FXS, and support the
notion that the field may be underestimating the neurobiological heterogeneity underlying
autistic behavior.
One limitation of our study is that the brain volume focused on regions-of-interest defined
by sulcal-gyral anatomy (e.g., cerebral lobes) or identifiable subcortical boundaries (e.g.,
hippocampus, caudate). This volumetric approach is complementary to, yet different from a
voxel-level morphological approach for elucidating fine-grained neuroanatomical variations,
which was used to analyze this FXS cohort in an earlier study from our group.11–13 In this
previous study we detected FXS specific trajectories in various parts of the cerebral cortex,
the thalamus and the basal forebrain. Another, limitation is the size of our subgroups of the
controls (DD and TYP) was also modest and is a limitation, although the longitudinal design
allows for increased power to detect significant differences, particularly with the effect sizes
we observed in the basal ganglia. We only examined male children with the full mutation,
and therefore our findings may not generalize to females or individuals with the
premutation. Lastly, the measures we employed for the behavioral assessment (e.g., ADI-R,
ADOS) were developed for categorical diagnosis of autistic disorder and we were therefore
limited in the ability to look at dimensional qualities across time.
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Longitudinal trajectories for total brain volume (TBV) in between children with fragile X
syndrome (FXS), idiopathic autism (iAUT), and controls. Note: Red = iAUT; Blue = FXS;
Black = Controls.
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Percent increase in cortical lobe tissue volumes in Fragile X Syndrome (FXS) and idiopathic
autism (iAUT) groups compared to controls (represented by x axis). Note: Percent
differences between FXS and iAUT groups compared to controls (y axis) are shown after
adjusting age and IQ. * indicates comparisons significant at p<.05 after controlling for total
brain volume (TBV), age, and IQ.
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Trajectories for group differences in caudate and amydala volumes.
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Table 1
Sample Descriptives.
Time 1 Age (yrs) Time 2 Age (yrs)
Group n M (SD) n M (SD)
Fragile X Syndrome 53 2.9 (.62) 39 4.92 (.80)
Autism Spectrum Disorder 68 2.79 (.39) 44 5.04 (.43)
Typically Developing 31 2.55 (.59) 19 4.59 (.51)
Developmental Delay 19 2.96 (.50) 7 5.13 (.62)
Note: All subjects were male. yrs = years.
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Table 2
Cognitive and adaptive functioning of subjects
Mullena Vinelandb
Group n M (SD) M (SD)
FXS
 time 1 53 54.87 (9.07) 62.13 (9.74)
 time 2 39 52.21 (9.85) 51.33 (8.87)
ASD
 time 1 68 54.97 (10.98) 62.74 (8.50)
 time 2 44 63.23 (22.57) 56.74 (15.21)
TYP
 time 1 31 109.55 (17.24) 97.20 (12.67)
 time 2 19 112.89 (14.76) 93.83 (11.97)
DD
 time 1 19 55.47 (7.53) 64.16 (11.73)
 time 2 7 58.86 (11.22) 56.43 (13.75)
Note: ASD = autism spectrum disorder; DD = developmental delay; FXS = Fragile X Syndrome; TYP = typically developing children.
a
Mullen Scales of Early Learning (MSEL) Early Learning Composite (ELC) Standard Score
b
Vineland Adaptive Behavior Composite (VABS) Standard Score
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Table 4
Group comparisons for Fragile X Syndrome (FXS) versus controls for global and lobar brain volumes
Volume Comparisons (FXS vs. Controls)
Diff SE p %
Total Brain Volume 73.2 26.3 .006 6%
Total Tissue Volume 64.6 23.5 .007 6%
Total Gray Matter 43.2 16.9 .012 6%
Total White Matter 21.4 7.0 .003 7%
Cerebral Spinal Fluid 8.6 5.2 .10 7%
Cerebellum 0.41 2.2 .85 0%
  Gray 1.44 1.9 .45 1%
  White −1.03 0.4 .02 −5%
Cerebral Cortex −3.01 4.1 .46 0%
  Gray −7.4 3.3 .03 −1%
  White 4.38 2.3 .06 2%
Parietal-Occipital −1.5 3.1 .63 0%
  Gray −2.1 2.3 .34 −1%
  White 0.7 1.4 .63 1%
Temporal 2.3 2.1 .28 1%
  Gray −1.9 1.7 .27 −1%
  White 4.2 0.8 <.001 10%
Frontal −5.9 3.5 .09 −2%
  Gray −6.1 2.6 .02 −2%
  White 0.2 1.5 .90 0%
Note: Table 4 presents the group differences (Diff) and standard error (SE) for total and lobar brain volumes at 3.5 years of age (the approximate
mean age for our sample) after adjusting for age and IQ. Regional comparisons (cerebellum, cerebral cortical volume, cortical lobes) are show with
adjustments controlling for age, IQ, and total brain volume (TBV).
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Table 5
Group comparisons for selected substructure volumes controlling for age, IQ, and total brain volume (TBV).
Region FXS v Controls FXS v DD FXS v TYP FXS v iAUT
Diff (SE), % diff Diff (SE), % diff Diff (SE), % diff Diff (SE), % diff
Caudate nucleus
 Total 2.42 (.3), 34% *** 2.45 (.4), 35% *** 2.38 (.4), 33% *** 2.14 (.3), 29% ***
 Right 1.20 (.2),33% *** 1.21 (.2), 34% *** 1.18 (.2), 32% *** 1.07 (.1), 29% ***
 Left 1.22 (.2), 35% *** 1.24 (.2), 36% *** 1.20 (.2), 34% *** 1.06 (.1), 29% ***
Putamen
 Total 0.45 (.2), 5%* 0.35 (.3), 4% 0.56 (.2), 7% * 0.50 (.2), 6% **
 Right 0.24 (.1), 6% * 0.19 (.1), 5% 0.29 (.1), 7% * 0.28 (.1), 7% ***
 Left 0.22 (.1), 5% * 0.16 (.1), 4% 0.27 (.1), 6% * 0.22 (.1), 5% **
Globus pallidus
 Total 0.41 (.1), 15% *** 0.44 (.1), 16% *** 0.39 (.1), 14% *** 0.22 (.1), 7% **
 Right 0.21 (.1), 15% *** 0.23 (.1), 17% *** 0.19 (.1), 13% *** 0.14 (.04), 10% ***
 Left 0.21 (.1), 15% *** 0.21 (.1), 15% ** 0.20 (.1), 15% *** 0.08 (.04), 5%
Amygdala
 Total −0.30 (.1), −9% * −0.39 (.2), −11% * −0.21 (.2), −6% −0.66 (.1), −17% ***
 Right −0.16 (.1), −9% * −0.18 (.1), −10% * −0.13 (.1), −8% −0.37 (.1), −18% ***
 Left −0.14 (.1), −8% * −0.21 (.1), −11% * −0.08 (.1), −5% −0.29 (.1), −16% ***
Hippocampus
 Total 0.23 (.2), −4% 0.23 (.2), −4% −0.23 (.2), −4% −0.34 (.1), −6% **
 Right 0.04 (.1), −1% −0.06 (.2), −2% −0.01 (.1), 0% −0.07 (.1), −2%
 Left 0.19 (.1), −7% −0.17 (.1), −6% −0.21 (.1), −7% * −0.28 (.1), −9% ***
Note: Fragile X Syndrome (FXS) group refers to entire sample of children with FXS. The Control group contained both developmentally delayed
(DD) and typically developing (TYP) subjects, but comparisons with the DD and TYP subgroups are also displayed separately. Diff = group
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Table 6
Autism Diagnostic Interview–Revised (ADI-R) subdomain scores for Fragile X Syndrome (FXS) in the
subgroup with autism (FXS+A), without autism (FXS-A), and the autism spectrum disorder (ASD) group
FXS+Aut FXS-A ASD
ADI-R subdomain M(SD) M(SD) M (SD)
Communication
 Verbal n=9 n=17 n=58
8.33 (3.4) 8.47 (3.5) 9.47 (2.6)
 Nonverbal n=14 n=25 n=60
10.43 (1.9) 6.48 (3.8) 10.73 (2.2)
Social 17.47 (3.8) 9.87 (5.8) 18.13 (6.2)
Ritualistic-repetitive 4.87 (1.8) 3.13 (1.8) 4.93 (1.8)
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Table 7
Comparisons for Fragile X Syndrome (FXS) subgroups compared to idiopathic autism (iAUT) and each other
for selected substructure volumes after controlling for age, IQ, and total brain volume (TBV). Comparisons for
Fragile X Syndrome with autism (FXS+Aut) vs. Fragile X Syndrome without autism (FXS-Aut) are shown
after controlling for age and TBV only.
Region FXS+Aut vs. iAUT FXS-Aut vs. iAUT FXS+Aut vs. FXS-Aut
Diff (SE), % diff Diff (SE), % diff Diff (SE), % diff
Caudate nucleus
 Total 2.31 (.3), 31% *** 1.73 (.3), 23% *** .63 (.4), 7%
 Right 1.16 (.2), 31% *** 0.88 (.1), 24% *** .29 (.2), 6%
 Left 1.16 (.2), 32% *** 0.84 (.1), 23% *** .33 (.2), 7%
Putamen
 Total 0.43 (.2), 5% * 0.35 (.3), 4% −.27 (.3), −3%
 Right 0.24 (.1), 6% * 0.19 (.1), 5% −.15 (.1), −3%
 Left 0.19 (.1), 5% 0.16 (.1), 4% −.12 (.2), −3%
Globus pallidus
 Total 0.26 (.1), 9% *** 0.12 (.1), 4% .13 (.1), 4%
 Right 0.16 (.05), 11% *** 0.08 (.04), 6% * .07 (.1), 5%
 Left 0.10 (.1), 7% 0.04 (.04), 2% .06 (.1), 4%
Amygdala
 Total −0.68 (.1), −17% *** −0.63 (.1), −11% *** −.01 (.2), 0%
 Right −0.38 (.1), −19% *** −0.34 (.1), −10% *** −.02 (.1), −1%
 Left −0.30 (.2), −16% *** −0.29 (.1), −11% *** .01 (.1), 1%
Hippocampus
 Total −0.39 (.2), −7% * −0.17 (.2), −3% −.17 (.2), −3%
 Right −0.08 (.1), −3% −0.05 (.1), −2% −.05 (.1), −2%
 Left −0.31 (.1), −11% *** −0.12 (.1), −4% −12 (.1), −4%
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